According to Direxion CEO Douglas Yones, Eli Lilly and Palo Alto Networks are prime candidates for leveraged trading.

In the latest trading session, Eli Lilly (LLY) closed at $852.35, marking a -1.45% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. On the other hand, ...

Organovo (ONVO) announced the close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (LLY). The ...

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

The current US Commerce Secretary - Howard Luttnick - has once again targeted Ireland, calling our country his 'favourite tax ...

Following in the footsteps of blockbuster drugs such as Ozempic and Wegovy—both powered by semaglutide—Mounjaro (approved for ...

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...

By influencing multiple body systems simultaneously, tirzepatide offers a powerful approach to managing both diabetes and ...

The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...